BridgeBio Pharma, Inc.
acoramidis
transthyretin amyloid cardiomyopathy (ATTR-CM)
Resolved
137days ago
Phase 3 readout · Feb 20, 2026
What's at stake
Phase 3 trial results for acoramidis in transthyretin amyloid cardiomyopathy (ATTR-CM) are due Feb 20, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 16h ago
“7,804 unique patient prescriptions have been written by 1,856 unique prescribers since FDA approval in November 2024”